The pharmacological landscape of chronic subdural hematoma: a systematic review and network meta-analysis of randomized and non-randomized controlled studies

Abstract

Background: There are various treatment modalities for chronic subdural hematoma (CSDH) and there is extensive debate surrounding pharmaceutical interventions. There is no consensus regarding the relative efficacy and safety of multiple treatment modalities. This study aims to investigate this issue and offer potential clinical recommendations. Methods: We searched PubMed, Web of Science, Embase and the Cochrane Library from January 2000 to May 2023 to identify randomized and nonrandomized controlled studies reporting one or more outcomes associated with the pharmacologic management of CSDH. The primary outcomes of interest included recurrence, favorable prognosis and adverse events, while the secondary outcomes included a reduction in hematoma volume and mortality. Pooled estimates, credible intervals and odds ratios were calculated for all outcomes using a fixed effects model. Confidence in network meta-analysis judgments were employed to stratify the evidential quality. This study was registered with PROSPERO: CRD42023406599. Results: The search strategy yielded 656 references; ultimately, 36 studies involving 8082 patients fulfilled our predefined inclusion criteria. The findings suggested that statins + glucocorticoids (GCs) ranked highest for preventing recurrence, improving prognosis and facilitating hematoma absorption. Tranexamic acid ranked second highest for preventing recurrence. Statins were found to be the preferred drug intervention for decreasing mortality and preventing adverse events. Antithrombotic agents ranked lowest in terms of decreasing mortality and improving prognosis. Conclusions: Our findings indicate that statins + GCs may be the most effective treatment modality for preventing recurrence, improving patient prognosis and facilitating hematoma absorption. In terms of reducing mortality and preventing adverse events, statins may be superior to other pharmacological interventions. Routine use of GCs is not suggested for patients with CSDH. Further prospective research is needed to directly compare the efficacy and superiority of various pharmaceutical interventions targeting CSDH to reinforce and validate our findings.

Keywords

Chronic subdural hematoma / Pharmacological interventions / Recurrence / Statins / Glucocorticoids / Meta-analysis / Randomized controlled studies

References

[1] Soleman J, Lutz K, Schaedelin S, Kamenova M, Guzman R, Mariani L, et al. Subperiosteal vs subdural drain after Burr-hole drainage of chronic subdural hematoma: a randomized clinical trial (cSDH-drain-trial). Neurosurgery 2019; 85: E825-34.

[2] Santarius T, Kirkpatrick PJ, Ganesan D, Chia HL, Jalloh I, Smielewski P, et al. Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trial. Lancet 2009; 374: 1067-73.

[3] Kolias AG, Chari A, Santarius T, Hutchinson PJ. Chronic subdural haematoma: modern management and emerging therapies. Nat Rev Neurol 2014; 10: 570-8.

[4] Brennan PM, Kolias AG, Joannides AJ, Shapey J, Marcus HJ, Gregson BA, et al. The management and outcome for patients with chronic subdural hematoma: a prospective, multicenter, observational cohort study in the United Kingdom. J Neurosurg 2017; 127: 732-9.

[5] Almenawer SA, Farrokhyar F, Hong C, Alhazzani W, Manoranjan B, Yarascavitch B, et al. Chronic subdural hematoma management: a systematic review and meta-analysis of 34,829 patients. Ann Surg 2014; 259: 449-57.

[6] Miranda LB, Braxton E, Hobbs J, Quigley MR. Chronic subdural hematoma in the elderly: not a benign disease. J Neurosurg 2011; 114: 72-6.

[7] Tommiska P, Korja M, Siironen J, Kaprio J, Raj R. Mortality of older patients with dementia after surgery for chronic subdural hematoma: a nationwide study. Age Ageing 2021; 50: 815-21.

[8] Lin MS. Subdural lesions linking additional intracranial spaces and chronic subdural hematomas: a narrative review with mutual correlation and possible mechanisms behind high recurrence. Diagnostics (Basel) 2023; 13: 235-48.

[9] Kung WM, Lin MS. CT-based quantitative analysis for pathological features associated with postoperative recurrence and potential application upon artificial intelligence: a narrative review with a focus on chronic subdural hematomas. Mol Imaging 2020; 19: 1536012120914773.

[10] Uno M. Chronic subdural hematoma-evolution of Etiology and surgical treatment. Neurol Med Chir (Tokyo) 2023; 63: 1-8.

[11] Henry J, Amoo M, Kissner M, Deane T, Zilani G, Crockett MT, et al. Management of Chronic Subdural Hematoma: a systematic review and component network meta-analysis of 455 studies with 103 645 cases. Neurosurgery 2022; 91: 842-55.

[12] Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition Chichester (UK): John Wiley & Sons, 2019.

[13] Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777-84.

[14] Zhong S, Liu T, Zhai Q, Zhang X, Jing H, Li K, et al. Impacts of statin therapy strategies on incidence of ischemic cerebrovascular events in patients with aneurysmal subarachnoid Hemorrhage: a systematic review and Bayesian network meta-analysis. Neurosurgery 2023; 93: 24-32.

[15] Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.

[16] Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med 2020; 17: e1003082.

[17] Weigel R, Schmiedek P, Krauss JK. Outcome of contemporary surgery for chronic subdural haematoma: evidence based review. J Neurol Neurosurg Psychiatry 2003; 74: 937-43.

[18] Feghali J, Yang W, Huang J. Updates in chronic subdural hematoma: epidemiology, Etiology, pathogenesis, treatment, and outcome. World Neurosurg 2020; 141: 339-45.

[19] Hutchinson PJ, Edlmann E, Bulters D, Zolnourian A, Holton P, Suttner N, et al. Trial of dexamethasone for chronic subdural hematoma. N Engl J Med 2020; 383: 2616-27.

[20] Miah IP, Herklots M, Roks G, Peul WC, Walchenbach R, Dammers R, et al. Dexamethasone therapy in symptomatic chronic subdural hematoma (DECSA-R): a retrospective evaluation of initial corticosteroid therapy versus primary surgery. J Neurotrauma 2020; 37: 366-72.

[21] Berghauser Pont LM, Dammers R, Schouten JW, Lingsma HF, Dirven CM. Clinical factors associated with outcome in chronic subdural hematoma: a retrospective cohort study of patients on preoperative corticosteroid therapy. Neurosurgery 2012; 70: 873-80. discussion 880.

[22] Yao Z, Hu X, Ma L, You C. Dexamethasone for chronic subdural haematoma: a systematic review and meta-analysis. Acta Neurochir 2017; 159: 2037-44.

[23] Miah IP, Holl DC, Blaauw J, Lingsma HF, den Hertog HM, Jacobs B, et al. Dexamethasone versus surgery for chronic subdural hematoma. N Engl J Med 2023; 388: 2230-40.

[24] Jiang R, Zhao S, Wang R, Feng H, Zhang J, Li X, et al. Safety and efficacy of atorvastatin for chronic subdural hematoma in Chinese patients: a randomized ClinicalTrial. JAMA Neurol 2018; 75: 1338-46.

[25] Wang D, Gao C, Xu X, Chen T, Tian Y, Wei H, et al. Treatment of chronic subdural hematoma with atorvastatin combined with low-dose dexamethasone: phase II randomized proof-of-concept clinical trial. J Neurosurg 2020; 134: 235-43.

[26] Liu T, Zhao Z, Huang J, Zhu X, Chen W, Lin K, et al. Multimodality management for chronic subdural hematoma in China: protocol and characteristics of an ambidirectional, nationwide, multicenter registry study. Chin Neurosurg J 2024; 10: 4.

[27] Quan W, Zhang Z, Li P, Tian Q, Huang J, Qian Y, et al. Role of regulatory T cells in atorvastatin induced absorption of chronic subdural hematoma in rats. Aging Dis 2019; 10: 992-1002.

[28] Wang D, Li T, Wei H, Wang Y, Yang G, Tian Y, et al. Atorvastatin enhances angiogenesis to reduce subdural hematoma in a rat model. J Neurol Sci 2016; 362: 91-9.

[29] Li T, Wang D, Tian Y, Yu H, Wang Y, Quan W, et al. Effects of atorvastatin on the inflammation regulation and elimination of subdural hematoma in rats. J Neurol Sci 2014; 341: 88-96.

[30] Liu X, Gao C, Yuan J, Xiang T, Gong Z, Luo H, et al. Subdural haematomas drain into the extracranial lymphatic system through the meningeal lymphatic vessels. Acta Neuropathol Commun 2020; 8: 16.

[31] Gao C, Wei Y, Zhang X, Huang J, Nie M, Liu X, et al. Craniocervical manual lymphatic drainage increases the efficiency of atorvastatin-based treatment of chronic subdural hematoma. Transl Stroke Res 2022; 14: 667-77.

[32] Jiang RC, Wang D, Zhao SG, Wang RZ, Kang Z, Zhu XG, et al. Atorvastatin combined with dexamethasone in chronic subdural haematoma (ATOCH II): study protocol for a randomized controlled trial. Trials 2021; 22: 905.

[33] Liu T, Wu L, Xue R, Ding H. Efficacy and safety of tranexamic acid in aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. Am J Emerg Med 2021; 50: 646-53.

[34] McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs 2012; 72: 585-617.

[35] Miyakoshi A, Nakatani E, Kaneda H, Hawke P, Sasaki H, Urano T, et al. Administration of Tranexamic Acid after Burr hole craniotomy reduced postoperative recurrence of chronic subdural hematoma in a Japanese regional population. Neurosurgery 2023; 93: 1160-7.

[36] Yamada T, Natori Y. Prospective study on the efficacy of orally administered Tranexamic acid and Goreisan for the prevention of recurrence after chronic subdural hematoma Burr hole surgery. World Neurosurg 2020; 134: e549-53.

[37] Gaist D, Garcia Rodriguez LA, Hellfritzsch M, Poulsen FR, Halle B, Hallas J, et al. Association of Antithrombotic Drug use with subdural hematoma risk. JAMA 2017; 317: 836-46.

[38] Poon MTC, Al-Shahi SR. Association between antithrombotic drug use before chronic subdural haematoma and outcome after drainage: a systematic review and meta-analysis. Neurosurg Rev 2018; 41: 439-45.